Scientific Program

Thursday, October 19
Hall B
17:15-17:45 ECP Delphi Panel – Understanding the evolving practices of prescribing ECP in the real world
Industry-supported Meet the Expert Session
17:45-18:00 Technical Break
18:00-18:30 CMV Management post HSCT
Industry-supported Meet the Expert Session
Friday, October 20
Hall A
08:00-08:30 Good Morning Coffee
08:30-09:30 Cell Therapy Today: Scientific evolution of T-Cell Approaches
Industry-supported Pre-Congress Workshop
09:30-09:40 Short Break
09:40-09:45 Welcome Note: Nicolaus Kröger, Germany and Arnon Nagler, Israel
09:45-11:05 Opening Session: BiTE vs CAR-T
09:45-10:15 Controversy: BiTE vs CAR-T in relapsed/refratory multiple myeloma (MM)
Moderator: Arnon Nagler, Israel
09:45-10:00 Pro BiTE: Evangelos Terpos, Greece
10:00-10:15 Pro CAR-T: Nikhil Munshi, USA
10:15-10:45 Controversy: BiTE vs CAR-T in DLBCL
Moderator: Nicolaus Kröger, Germany
10:15-10:30 Pro BiTE: Carmelo Carlo-Stella, Italy
10:30-10:45 Pro CAR-T: Michael Bishop, USA
10:45-11:05 Panel discussion: All session faculty
11:05-11:25 Coffee Break, Poster Viewing and Visit Exhibition
Hall A Hall B
11:25-12:45 Session 1: AML Session 2: MDS
11:25-11:55 Controversy: Do we need MRD negativity pre-allo HSCT in AML?
Moderator: Charles Craddock, UK
Controversy: Should we perform a transplant in MDS patients with p53?
Moderator: Alessandro Rambaldi, Italy
11:25-11:40 Yes: Roland Walter, USA Yes: Bart Lee Scott, USA
11:40-11:55 No: Michael Heuser, Germany No: Magnus Tobiasson, Sweden
11:55-12:25 Controversy: Is there a role for salvage therapy pre-allo HSCT in refractory/relapsed AML?
Moderator: Arnon Nagler, Israel
Controversy: Are there patients with low IPSSR who benefit from early transplant?
Moderator: Alessandro Rambaldi, Italy
11:55-12:10 Yes: Charles Craddock, UK Yes: Ibrahim Yakoub-Agha, France
12:10-12:25 No: Johannes Schetelig, Germany No: Matteo Della Porta, Italy
12:25-12:45 Panel discussion: All session faculty Panel discussion: All session faculty
12:45-13:30 Lunch Pick-up, Poster Viewing and Visit Exhibition
13:30-14:30 Clinical outcomes in acute leukemias – a case-based approach
Industry-supported Lunch Symposium
(Hall A)
14:30-14:45 Short Break
Hall A Hall B
14:45-16:15 Session 3: Allogeneic transplantation Session 4: Lymphoma
14:45-15:15 Controversy: Is treosulfan conditioning the new standard for allogeneic SCT in MDS?
Moderator: Bart Lee Scott, USA
Controversy: Is there still a role for auto transplant in MCL?
Moderator: Arnon Nagler, Israel
14:45-15:00 Yes: Avichai Shimoni, Israel 14:45-15:00 – Yes: Ali Bazarbachi, Lebanon
15:00-15:15 No: Alessandro Rambaldi, Italy 15:00-15:15 – No: Georg Hess, Germany

15:15-15:30 – Discussion

15:15-15:45 Controversy: Are venetoclax combinations replacing anthracycline/araC containing induction regimen prior to allogeneic stem cell transplantation?
Moderator: Michael Heuser, Germany
Controversy: Is there is still a role for allo transplant in Hodgkin lymphoma?
Moderator: Arnon Nagler, Israel
15:15-15:30 Yes: Claudio Cerchione, Italy 15:30-15:45 – Yes: Ali Bazarbachi, Lebanon
15:30-15:45 No: Lars Bullinger, Germany 15:45-16:00 – No: Nicolaus Kröger, Germany
15:45-16:15 Panel discussion: All session faculty 16:00-16:15 – Discussion
16:15-16:45 Coffee Break, Poster Viewing and Visit Exhibition
Hall A Hall B
16:45-18:15 Session 5: GvHD Session 6: MPN
16:45-17:15 Controversy: Is PTCy/MMF/CNI or ATG/MMF/CNI the standard of care GvHD prophylaxis in MUD?
Moderator: Corey Cutler, USA
Controversy: Should patients be monitored post allo with molecular markers?
Moderator: Rachel Salit, USA
16:45-17:00 PTCy: Leonido Luznik, USA Yes: Nicolaus Kröger, Germany
17:00-17:15 ATG: Francesca Bonifazi, Italy No: Andrea Bacigalupo, Italy
17:15-17:45 Controversy: Are JAK inhibitors the new standard for all SR-acute and chronic GvHD manifestations?
Moderator: Leonido Luznik, USA
Controversy: Should KRAS or others be added to ASXL1, SRSF2 and EZH2 as bad predictors indicating transplants in myelofibrosis?
Moderator: Andrea Bacigalupo, Italy
17:15-17:30 Yes: Robert Zeiser, Germany Yes: Nico Gagelmann, Germany
17:30-17:45 No: Corey Cutler, USA No: Rachel Salit, USA
17:45-18:15 Panel discussion: All session faculty Panel discussion: All session faculty
18:15-19:15 Poster Walk and Awards Session
(Poster Area)
Saturday, October 21
Hall A Hall B
09:15-10:45 Session 7: Donor selection Session 8: Haploidentical transplants
09:15-09:45 Controversy: Is selecting according to HLA including HLA B leader and permissive MM for allogeneic transplants in the era of PTCy still needed?
Moderator: Robert Soiffer, USA
Controversy: Does PTCy increase late relapses and late infections post haploidentical transplants?
Moderator: Bart Lee Scott, USA
09:15-09:30 Yes: Katharina Fleischhauer, Germany Yes: Olaf Penack, Germany
09:30-09:45 No: Bronwen Shaw, USA No: Christopher Kanakry, USA
09:45-10:15 Controversy: Is younger MUD better than HLA-sibling in older MDS and AML patients?
Moderator: Bronwen Shaw, USA
Controversy: Does PTCy in haplo transplant for children replace ex vivo T-cell depletion?
Moderator: Christopher Kanakry, USA
09:45-10:00 Yes: Wael Saber, USA Yes: Michael Pulsipher, USA
10:00-10:15 No: Robert Soiffer, USA No: Peter Bader, Germany
10:15-10:45 Panel discussion: All session faculty Panel discussion: All session faculty
10:45-11:15 Coffee Break, Poster Viewing and Visit Exhibition
Hall A Hall B
11:15-12:45 Session 9: Immunotherapy I Session 10: ALL
11:15-11:45 Controversy: Did we progress with CAR-T in AML?
Moderator: Stephan Mielke, Sweden
Controversy: Are we ready to abandon allo in ALL?
Moderator: Nicola Gökbuget, Germany
11:15-11:30 Yes: Saar Gill, USA Yes: Nicholas Short, USA
11:30-11:45 No: Marion Subklewe, Germany No: Arnon Nagler, Israel
11:45-12:15 Controversy: TCR editing vs CAR in malignancies
Moderator: Marion Subklewe, Germany
Controversy: Do we need allo post CAR in ALL?
Moderator: Ibrahim Yakoub-Agha, France
11:45-12:00 Pro TCR: Chiara Bonini, Italy Yes: Peihua Lu, China
12:00-12:15 Pro CAR: Stephan Mielke, Sweden No: Nicola Gökbuget, Germany 
12:15-12:45 Panel discussion: All session faculty Panel discussion: All session faculty
12:45-13:30 Lunch Pick-up, Poster Viewing and Visit Exhibition
13:30-15:00 CMV-Management: Up to date Management of CMV in HSCT and CAR-T
Industry-supported Lunch Symposium
(Hall A)
15:00-15:15 Short Break
Hall A Hall B
15:15-16:45 Session 11: Immunotherapy II Session 12: Pediatrics and non-malignancies
15:15-15:45 Controversy: Are CAR-T cells replacing autologous SCT in autoimmune disease?
Moderator: Nicolaus Kröger, Germany
Controversy: SCT vs gene therapy in sickle cell anemia and thalassemia
Moderator: Selim Corbacioglu, Germany
15:15-15:30 Yes: Dominique Farge, France 15:15-15:30 – SCT: Suradej Hongeng, Thailand
15:30-15:45 No: Riccardo Saccardi, Italy 15:30-15:45 – Gene therapy: Markus Mapara, USA
15:45-16:00 – Discussion
15:45-16:15 Controversy: Is point-of-care production of CAR-T cells the favorable way to go forward?
Moderator: Claudio Cerchione, Italy
Controversy: Allogeneic/Gene-therapy for autoimmune disease
Moderator: Peter Bader, Germany
15:45-16:00 Yes: Stephan Mielke, Sweden 16:00-16:15 – Yes: Selim Corbacioglu, Germany
16:00-16:15 No: Christian Chabannon, France 16:15-16:30 – No: Tobias Alexander, Germany
16:30-16:45 – Discussion
16:15-16:45 Panel discussion: All session faculty
16:45 Closing Remarks: Nicolaus Kröger, Germany and Arnon Nagler, Israel
(Hall A)